PASADENA

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

Thématique(s) / pathologie(s)

  • Maladie de Parkinson

Promoteur

Hoffmann-La Roche

Publication(s) scientifique(s)

  • Jankovic J et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.

Statut

Résultats publiés

Partager

Mis à jour le 25 janvier 2023